AbbVie Inc (ABBV)vsAlignment Healthcare LLC (ALHC)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ALHC
Alignment Healthcare LLC
$15.37
+1.99%
HEALTHCARE · Cap: $4.08B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1376% more annual revenue ($62.82B vs $4.26B). ABBV leads profitability with a 5.8% profit margin vs 0.5%. ABBV trades at a lower P/E of 105.1x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ALHC
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+5.8%
Fair Value
$21.64
Current Price
$15.37
$6.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 33.3% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Trading at 15.4x book value
0.0% earnings growth
0.5% margin — thin
Operating margin of 1.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ALHC
The strongest argument for ALHC centers on Revenue Growth. Revenue growth of 33.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ALHC
The primary concerns for ALHC are Price/Book, EPS Growth, Profit Margin. A P/E of 197.5x leaves little room for execution misses. Debt-to-equity of 1.59 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while ALHC is a hypergrowth play — different risk/reward profiles.
ALHC carries more volatility with a beta of 1.15 — expect wider price swings.
ALHC is growing revenue faster at 33.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 48/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Alignment Healthcare LLC
HEALTHCARE · HEALTHCARE PLANS · USA
Alignment Healthcare, Inc. provides a consumer-centric platform that provides personalized healthcare to seniors in the United States. The company is headquartered in Orange, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?